Inflammation as a new target in CV risk reduction - PACE-CME

Inflammation as a new target in CV risk reduction

Media formats available:

Recommended

Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Carolyn Lam, MD
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
- Aaron Wong, MD
Effect of SGLT2i on diuretic efficacy in acute heart failure
Effect of SGLT2i on diuretic efficacy in acute heart failure
ESC Congress 2023
Effect of SGLT2i on diuretic efficacy in acute heart failure